Trial Profile

A Phase 1, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REM 422 (Primary)
Indications Adenoid cystic carcinoma
Focus Adverse reactions
Sponsors Remix Therapeutics

Most Recent Events

02 May 2024 According to Remix Therapeutics media release, the first patient enrolled and dosed in this Phase 1 clinical trial
03 Jan 2024 Status changed from not yet recruiting to recruiting.
03 Jan 2024 According to Remix Therapeutics media release, REM-422, is expected to enter this Phase 1 clinical study for the treatment of recurrent or metastatic adenoid cystic carcinoma in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com